{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:48:49Z","timestamp":1782283729884,"version":"3.54.5"},"reference-count":36,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Transarterial radioembolization (TARE) plays an increasing role in the treatment of hepatocellular carcinoma (HCC). Several isotope platforms have been introduced; however, comparative data remain limited. We aimed to compare outcomes following Holmium-166 (Ho-166) and Yttrium-90 (Y-90) TARE in HCC patients. Methods: We retrospectively analyzed a prospectively maintained cohort of HCC patients treated with Ho-166 or Y-90 TARE between 2022 and 2024. Tumor burden and treatment response were assessed using contrast-enhanced CT or MRI. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan\u2013Meier method and further evaluated using multivariable Cox regression analyses adjusted for baseline confounders. Results: A total of 73 patients were analyzed, including 39 treated with Y-90 and 34 with Ho-166 TARE. Median follow-up duration was 20.9 months. No significant differences in OS or PFS were observed between treatment groups. Response outcomes, including objective response rate, complete response rate, and duration of response, were also comparable between groups. In the overall cohort, median OS was not reached in Barcelona Clinic Liver Cancer (BCLC) A or B patients and was 12.9 months in BCLC C patients. Median PFS was 20.1, 11.7, and 6.1 months in BCLC A, B, and C patients, respectively. Conclusions: Ho-166 and Y-90 TARE achieved favorable outcomes across different BCLC stages without significant differences in survival, treatment response, or duration of response between the two platforms. These findings further support the role of TARE in the management of patients with HCC.<\/jats:p>","DOI":"10.3390\/cancers18132039","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:37:17Z","timestamp":1782279437000},"page":"2039","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes Following Yttrium-90 and Holmium-166 Transarterial Radioembolization for Hepatocellular Carcinoma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-0053","authenticated-orcid":false,"given":"D\u00e1vid \u00c1d\u00e1m","family":"Korda","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, Heart and Vascular Centre, Semmelweis University, Hat\u00e1r\u0151r \u00fat 18, H-1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8136-7100","authenticated-orcid":false,"given":"D\u00e9nes Bal\u00e1zs","family":"Horv\u00e1thy","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Heart and Vascular Centre, Semmelweis University, Hat\u00e1r\u0151r \u00fat 18, H-1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Czibor","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Kor\u00e1nyi S\u00e1ndor utca 2, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domonkos","family":"N\u00e1dasdy-Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Kor\u00e1nyi S\u00e1ndor utca 2, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7979-9225","authenticated-orcid":false,"given":"Petra","family":"S\u00f3lymos","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical Imaging Centre, Semmelweis University, Kor\u00e1nyi S\u00e1ndor utca 2, H-1083 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oszk\u00e1r","family":"H\u00e1hn","sequence":"additional","affiliation":[{"name":"Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, \u00dcll\u0151i \u00fat 78, H-1082 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint","family":"Tegze","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Haematology, Semmelweis University, Szentkir\u00e1lyi u. 46, H-1088 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e1ra","family":"Werling","sequence":"additional","affiliation":[{"name":"Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, \u00dcll\u0151i \u00fat 78, H-1082 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Jak\u00f3","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Heart and Vascular Centre, Semmelweis University, Hat\u00e1r\u0151r \u00fat 18, H-1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szabolcs","family":"Tak\u00e1cs","sequence":"additional","affiliation":[{"name":"Faculty of Humanities, K\u00e1roli G\u00e1sp\u00e1r University of the Reformed Church in Hungary, K\u00e1lvin t\u00e9r 9, H-1091 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3881-837X","authenticated-orcid":false,"given":"P\u00e1l \u00c1kos","family":"De\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Heart and Vascular Centre, Semmelweis University, Hat\u00e1r\u0151r \u00fat 18, H-1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6083","authenticated-orcid":false,"given":"Andr\u00e1s","family":"Bibok","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Heart and Vascular Centre, Semmelweis University, Hat\u00e1r\u0151r \u00fat 18, H-1122 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular Carcinoma: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the Management of Hepatocellular Carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00270-020-02471-z","article-title":"CIRSE Standards of Practice on Thermal Ablation of Liver Tumours","volume":"43","author":"Crocetti","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC Strategy for Prognosis Prediction and Treatment Recommendations: The 2026 Update","volume":"84","author":"Reig","year":"2026","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3350\/cmh.2023.0076","article-title":"Transarterial Radioembolization versus Tyrosine Kinase Inhibitor in Hepatocellular Carcinoma with Portal Vein Thrombosis","volume":"29","author":"Hur","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jvir.2018.06.027","article-title":"Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma","volume":"29","author":"Gabr","year":"2018","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jvir.2023.10.011","article-title":"Radiation Major Hepatectomy Using Ablative Dose Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma 5 Cm or Larger","volume":"35","author":"Choi","year":"2024","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A Global Evaluation of Advanced Dosimetry in Transarterial Radioembolization of Hepatocellular Carcinoma with Yttrium-90: The TARGET Study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jvir.2023.03.011","article-title":"Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma","volume":"34","author":"Knight","year":"2023","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"S\u00f3lymos, P., R\u00e9dei, M., Turan, C., Szab\u00f3, B., \u00c1d\u00e1m, A., Moln\u00e1r, Z., Duray, G., Hegyi, P., and Horv\u00e1thy, D.B. (2025). Holmium-166 Radioembolization Is a Safe and Effective Locoregional Treatment for Primary and Secondary Liver Tumors: A Systematic Review and Meta-Analysis. Cancers, 17.","DOI":"10.3390\/cancers17111841"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.2967\/jnumed.122.263823","article-title":"Safety and Efficacy of 166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study","volume":"63","author":"Reinders","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1007\/s00270-024-03878-8","article-title":"Closed System Injection of Two Separate Vials of 166 Holmium-Labeled Microspheres in a Large Hepatocellular Carcinoma","volume":"47","author":"Bibok","year":"2024","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Korda, D., T\u00f3th, B., Horv\u00e1thy, D.B., Czibor, S., N\u00e1dasdy-Horv\u00e1th, D., S\u00f3lymos, P., Haboub-Sandil, A., Piros, L., and Bibok, A. (2026). Transarterial Radioembolization with Holmium-166-Labelled Microspheres as a Bridging Therapy for Liver Transplantation: A Case Report. Imaging, 1\u20134.","DOI":"10.1556\/1647.2025.00334"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1470-2045(12)70334-0","article-title":"Holmium-166 Radioembolisation in Patients with Unresectable, Chemorefractory Liver Metastases (HEPAR Trial): A Phase 1, Dose-Escalation Study","volume":"13","author":"Smits","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s00270-022-03187-y","article-title":"Holmium-166 Radioembolization: Current Status and Future Prospective","volume":"45","author":"Stella","year":"2022","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/j.semnuclmed.2019.01.008","article-title":"Holmium-166 Microsphere Radioembolization of Hepatic Malignancies","volume":"49","author":"Reinders","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00259-019-04460-y","article-title":"The Superior Predictive Value of 166Ho-Scout Compared with 99mTc-Macroaggregated Albumin Prior to 166Ho-Microspheres Radioembolization in Patients with Liver Metastases","volume":"47","author":"Smits","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2967\/jnumed.113.126839","article-title":"The Low Hepatic Toxicity per Gray of 90Y Glass Microspheres Is Linked to Their Transport in the Arterial Tree Favoring a Nonuniform Trapping as Observed in Posttherapy PET Imaging","volume":"55","author":"Walrand","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"d\u2019Abadie, P., Hesse, M., Louppe, A., Lhommel, R., Walrand, S., and Jamar, F. (2021). Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects. Molecules, 26.","DOI":"10.3390\/molecules26133966"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00270-025-04200-w","article-title":"CIRSE Standards of Practice for the Classification of Complications: The Modified CIRSE Classification System","volume":"49","author":"Filippiadis","year":"2026","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jvir.2009.05.030","article-title":"Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review","volume":"20","author":"Riaz","year":"2009","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1002\/hep4.2072","article-title":"Hepatic Decompensation after Transarterial Radioembolization: A Retrospective Analysis of Risk Factors and Outcome in Patients with Hepatocellular Carcinoma","volume":"6","author":"Reincke","year":"2022","journal-title":"Hepatol. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17562848231206995","DOI":"10.1177\/17562848231206995","article-title":"Portal Hypertension Increases the Risk of Hepatic Decompensation after 90Yttrium Radioembolization in Patients with Hepatocellular Carcinoma: A Cohort Study","volume":"16","author":"Rotger","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/hep.27057","article-title":"Unresectable Solitary Hepatocellular Carcinoma Not Amenable to Radiofrequency Ablation: Multicenter Radiology-Pathology Correlation and Survival of Radiation Segmentectomy","volume":"60","author":"Vouche","year":"2014","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus Standard Dosimetry Approach of Selective Internal Radiation Therapy in Patients with Locally Advanced Hepatocellular Carcinoma (DOSISPHERE-01): A Randomised, Multicentre, Open-Label Phase 2 Trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized Comparison of Selective Internal Radiotherapy (SIRT) versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma","volume":"38","author":"Pitton","year":"2015","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_29","first-page":"655","article-title":"Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and\/or Contralateral Portal Vein Invasion in IMbrave150","volume":"13","author":"Finn","year":"2024","journal-title":"Liver Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"81","DOI":"10.17998\/jlc.2023.12.25","article-title":"Comparison of Atezolizumab plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis","volume":"24","author":"Park","year":"2024","journal-title":"J. Liver Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.26014","article-title":"Yttrium-90 Radioembolization for Intermediate-Advanced Hepatocellular Carcinoma: A Phase 2 Study","volume":"57","author":"Mazzaferro","year":"2013","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cho, Y.Y., Lee, M., Kim, H.-C., Chung, J.W., Kim, Y.H., Gwak, G.-Y., Bae, S.H., Kim, D.Y., Heo, J., and Kim, Y.J. (2016). Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154986"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jhep.2012.09.003","article-title":"Radioembolization for Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Liver Function on Systemic Treatment Options at Disease Progression","volume":"58","author":"Memon","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","article-title":"Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma","volume":"31","author":"Zhan","year":"2020","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lopez-Lopez, V., Miura, K., Kuemmerli, C., Capel, A., Eshmuminov, D., Ferreras, D., Baroja-Mazo, A., Cascales-Campos, P., Jim\u00e9nez-Mascu\u00f1\u00e1n, M.I., and Pons, J.A. (2023). Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis. Cancers, 15.","DOI":"10.3390\/cancers15072122"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jhep.2026.01.008","article-title":"Yttrium-90 Radioembolization Is Associated with a Lower Risk of Liver Transplant Waitlist Dropout than Chemoembolization in Hepatocellular Carcinoma","volume":"84","author":"Kim","year":"2026","journal-title":"J. Hepatol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2039\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:05:07Z","timestamp":1782281107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":36,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132039"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132039","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}